Discussion about this post

User's avatar
Dave's avatar

An Oxford Professor gets > $1million a year from the Statin industry and then recommends to the UK government that everyone over 50 should be on statins when there is no data to support the value of statins, in fact the opposite is the case. Side effects are awful for > 30 of recipients. They use relative risk improvement of 30% for being on statins instead of absolute risk of 2% improvement for health risk with 30% risk of side effects. Cost benefit analysis doesn't add up.

Expand full comment
Dana Nicholson's avatar

Thanks. Am moving to England and will need to know

Expand full comment
8 more comments...

No posts